The New Hit Depression Treatment? A Ketamine-Derived Nasal Spray

from The Journal. · host The Wall Street Journal & Spotify Studios

After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson. Further Listening: -A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees. -America's Maternal Mental Health Crisis Further Reading: -J&J’s Ketamine-Derived Drug Is Taking Off -Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published Mar 21, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

The New Hit Depression Treatment? A Ketamine-Derived Nasal Spray

0:00 23:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Journal.?

This episode is 23 minutes long.

When was this The Journal. episode published?

This episode was published on March 21, 2025.

Can I download this The Journal. episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!